True Innovation In Women’s Health Hindered Because Conditions Are Not Fatal
Executive Summary
Drug developers and financiers discuss the biggest challenges delaying novel R&D in diseases effecting only women and how poor awareness of the debilitating symptoms that come with some conditions has led to a lack of emphasis on innovative research.
You may also be interested in...
Ferring Plots Genomics Path With Celmatix Pact
The firms have inked a collaboration which aims to explore individual differences in women’s responses to IVF treatment, improve success rates and reduce side effects such as ovarian hyper-stimulation syndrome.
AbbVie Prices Oral Endometriosis Drug Orilissa In Value Range, Focusing On Access
In addition to endometriosis, Orilissa (elagolix), developed by Neurocrine and licensed to Abbvie, is in Phase III for treating heavy bleeding associated with uterine fibroids.
Menopausal Symptoms Cooled By KaNDy's Dual Neurokinin Antagonist
Faster relief of debilitating menopausal symptoms in early-stage clinical trial results suggest a potential new class of products being evaluated by UK biotech KaNDy Therapeutics may be useful against the condition.